Abstract: Urinary tract infections (UTI) are the second most common infection, impacting nearly 50% of all women. Indeed, otherwise healthy, premenopausal women have a significantly greater incidence of urinary tract infection (UTI) than men, yet, conversely, male UTI is more persistent with greater associated morbidity. Additionally, both sexes are at significant risk of reinfection, suggesting that adaptive immune responses to this infection are insufficient. Our group is interested in identifying the mechanisms that govern sex bias and development of immunity in UTI. Our recent work demonstrates that resident macrophages impair the adaptive response and that IL-17 is a critical player in resolution of infection. Currently, we are dissecting the initial events leading to a specific effector cell response and how this response can be immunomodulated for improved therapeutics that obviate the need for antibiotics to treat multidrug resistant uropathogens.
Bio: Dr. Molly Ingersoll received her PhD studying host-pathogen interactions from NYU School of Medicine working with Arturo Zychlinsky at NYU and at the Max Planck Institute for Infection Biology in Berlin, Germany. A brief postdoctoral fellowship at Washington University School of Medicine, in St Louis, MO with Scott Hultgren, studying innate immunity to urinary tract infection was followed by a postdoctoral appointment at Mount Sinai Medical Center in NYC, investigating monocyte and dendritic cell biology. Dr. Ingersoll is a Group Leader with a team interested in immunity in the bladder in the context of infection and cancer at the Institut Pasteur in Paris.
Friday, July 31, 2020 at 10:00am to 11:00amVirtual Event
Persons with disabilities may submit a request for accommodations to participate in this event at UT Dallas' ADA website. You may also call (972) 883-5331 for assistance or send an email to ADACoordinator@utdallas.edu. All requests should be received no later than 2 business days prior to the event.